Rho kinase and Ca2+ entry mediate increased pulmonary and systemic vascular resistance in L-NAME-treated rats

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 293, Issue 5, 2007, Pages

  Dhaliwal, Jasdeep S ^a   Casey, David B ^a   Greco, Anthony J ^a   Badejo Jr , Adeleke M ^a   Gallen, Thomas B ^a   Murthy, Subramanyam N ^a   Nossaman, Bobby D ^b   Hyman, Albert L ^a   Kadowitz, Philip J ^a  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b Oschner Clinic   (United States)

Author keywords

Ca++ sensitization; HA 1077; Isradipine; N nitro L arginine methyl ester; Pulmonary vascular bed; Rho kinase pathway; Sodium nitroprusside

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; CALCIUM; FASUDIL; ISRADIPINE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE INHIBITOR; NITROPRUSSIDE SODIUM; RHO KINASE; 1 (5 ISOQUINOLINESULFONYL) 2 METHYLPIPERAZINE; CALCIUM CHANNEL BLOCKING AGENT; DRUG DERIVATIVE; ENZYME INHIBITOR; VASODILATOR AGENT;

ARTERIAL PRESSURE; ARTICLE; CALCIUM TRANSPORT; CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; HEART OUTPUT; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; LUNG VASOCONSTRICTION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; SYSTEMIC VASCULAR RESISTANCE; ANIMAL; LUNG CIRCULATION; METABOLISM; PATHOPHYSIOLOGY; PULMONARY ARTERY; SPRAGUE DAWLEY RAT; VASCULAR RESISTANCE; VASOCONSTRICTION;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ANIMALS; CALCIUM; CALCIUM CHANNEL BLOCKERS; ENZYME INHIBITORS; MALE; NG-NITROARGININE METHYL ESTER; NITROPRUSSIDE; PULMONARY ARTERY; PULMONARY CIRCULATION; RATS; RATS, SPRAGUE-DAWLEY; RHO-ASSOCIATED KINASES; VASCULAR RESISTANCE; VASOCONSTRICTION; VASODILATOR AGENTS;

EID: 36349027680     PISSN: 10400605     EISSN: 15221504     Source Type: Journal    
DOI: 10.1152/ajplung.00189.2007     Document Type: Article

References (56)

1. Abe K, Shimokawa H, Morikawa K, Uwatoku T, Oi K, Matsumoto Y, Hattori T, Nakashima Y, Kaibuchi K, Sueishi K, Takeshita A. Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats. Circ Res 94: 385-393, 2004.
2. Abe K, Tawara S, Oi K, Hizume T, Uwatoku T, Fukumoto Y, Kaibuchi K, Shimokawa H, Hiroaki J. Long-term inhibition of Rho-kinase ameliorates hypoxia-induced pulmonary hypertension in mice. Cardiovasc Pharmacol 48: 280-285, 2006.
3. Amano M, Ito M, Kimura K, Fukata Y, Chihara K, Nakano T, Matsuura Y, Kaibuchi K. Phosphorylation and activation of myosin by Rho-associated kinase (Rho-kinase). J Biol Chem 271: 20246-20249, 1996.
4. Amano M, Fukata Y, Kaibuchi K. Regulation and functions of Rho-associated kinase. Exp Cell Res 261: 44-51, 2000.
5. Archer SL, Tolins JP, Raij L, Weir EK. Hypoxic pulmonary vasoconstriction is enhanced by inhibition of the synthesis of an endothelium-derived relaxing factor. Biochem Biophys Res Commun 164: 1198-1205, 1989.
6. Asano T, Ikegaki I, Satoh S, Suzuki Y, Shibuya M, Takayasu M, Hidaka H. Mechanism of action of novel antivasospasm drug, HA1077. J Pharmacol Exp Ther 241: 1033-1040, 1987.
7. Baber SR, Hyman AL, Kadowitz PJ. Role of COX-1 and COX-2 in prostanoid generation and modulation of angiotensin II responses. Am J Physiol Heart Circ Physiol 285: H2399-H2410, 2003.
8. Baber SR, Deng W, Master RG, Bunnell BA, Taylor BK, Murthy SN, Hyman AL, Kadowitz PJ. Intratracheal mesenchymal stem cell administration attenuates monocrotaline-induced pulmonary hypertension and endothelial dysfunction. Am J Physiol Heart Circ Physiol 292: H1120-H1128, 2007.
9. Barer G, Emery C, Stewart A, Bee D, Howard P. Endothelial control of the pulmonary circulation in normal and chronically hypoxic rats. J Physiol 463: 1-16, 1993.
10. Barnard JW, Wilson PS, Moore TM, Thompson WJ, Taylor AE. Effect of nitric oxide and cyclooxygenase products on vascular resistance in dog and rat lungs. J Appl Physiol 74: 2940-2948, 1993.
11. Breitenlechner C, Gabel M, Hidaka H, Engh R, Bossemeyer D. Protein kinase a in complex with Rho-kinase inhibitors Y-27632, fasudil, and H-1152P: structural basis of selectivity. Structure 11: 1595-1607, 2003.
12. Budzyn K, Marley P, Sobey C. Targeting Rho and Rho-kinase in the treatment of cardiovascular disease. Trends Pharmacol Sci 27: 97-104, 2006.
13. + channel openers, aprikalim and pinacidil, on hypoxic pulmonary vasoconstriction. Eur J Pharmacol 263: 17-23, 1994.
14. Fagan K, Oka M, Bauer N, Gebb S, Ivy D, Morris K, McMurthy I. Attenuation of acute hypoxic pulmonary vasoconstriction and hypoxic pulmonary hypertension in mice by inhibition of Rho-kinase. Am J Physiol Lung Cell Mol Physiol 287: L656-L664, 2004.
15. ω-nitro-L-arginine methyl ester, LY83583, glybenclamide, and L158809 on pulmonary circulation. Eur J Pharmacol 263: 133-140, 1994.
16. Fukumoto Y, Matoba T, Ito A, Tanaka H, Kishi T, Hayashidani S, Abe K, Takeshita A, Shimokawa H. Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension. Heart 91: 391-392, 2005.
17. Guilluy C, Sauzeau V, Rolli-Derkinderen M, Guérin P, Sagan C, Pacaud P, Loirand G. Inhibition of RhoA/Rho-kinase pathway is involved in the beneficial effect of sildenafil on pulmonary hypertension. Br J Pharmacol 146: 1010-1018, 2005.
18. Hampl V, Herget J. Role of nitric oxide in the pathogenesis of chronic pulmonary hypertension. Physiol Res 49: 493-501, 2000.
19. Hasséssian H, Burnstock G. Interacting roles of nitric oxide and ATP in the pulmonary circulation of the rat. Br J Pharmacol 114: 846-850, 1995.
20. Hyman A, Hao Q, Tower A, Kadowitz P, Champion H, Gumsel B, Lippton H. Novel catheterization technique for the in vivo measurement of pulmonary vascular responses in rats. Am J Physiol Heart Circ Physiol 274: H1218-H1229, 1998.
21. Hyman AL, Kadowitz PJ. Pulmonary vasodilator activity of prostacyclin (PGI2) in the cat. Circ Res 45: 404-409, 1979.
22. Hyman AL, Kadowitz PJ. Tone-dependent responses to acetylcholine in the feline pulmonary vascular bed. J Appl Physiol 64: 2002-2009, 1988.
23. Hyvelin JM, Howell K, Nichol A, Costello CM, Preston RJ, McLoughlin P. Inhibition of Rho-kinase attenuates hypoxia-induced angiogenesis in the pulmonary circulation. Circ Res 97:185-191, 2005.
24. Ishikura K, Yamada N, Ito M, Ota S, Nakamura M, Isaka N, Nakano T. Beneficial acute effects of Rho-kinase inhibitor in patients with pulmonary arterial hypertension. Circ J 70: 174-178, 2006.
25. Ishizaki T, Maekawa M, Fujisawa K, Okawa K, Iwamatsu A, Fujita A, Watanabe N, Saito Y, Kakizuka A, Morii N, Narumiya S. The small GTP-binding protein Rho binds to and activates a 160 kDa Ser/Thr protein kinase homologous to myotonic dystrophy kinase. EMBO J 15: 1885-1893, 1996.
26. 2+ desensitization in pulmonary vascular smooth muscle through inhibition of RhoA/Rho-kinase signaling. Am J Physiol Lung Cell Mol Physiol 287: L1220-L1229, 2004.
27. Jiang B, Tawara S, Abe K, Takaki A, Fukumoto Y, Shimokawa H. Acute vasodilator effect of fasudil, a Rho-kinase inhibitor, in monocrotaline-induced pulmonary hypertension in rats. J Cardiovasc Pharmacol 49: 85-89, 2007.
28. Kawano Y, Fukata Y, Oshiro N, Amano M, Nakamura T, Ito M, Matsumura F, Inagaki M, Kaibuchi K. Phosphorylation of myosin-binding subunit (MBS) of myosin phosphatase by Rho-kinase in vivo. J Cell Biol 147: 1023-1038, 1999.
29. Kimura K, Ito M, Amano M, Chihara K, Fukata Y, Nakafuku M, Yamamori B, Feng J, Nakano T, Okawa K, Iwamatsu A, Kaibuchi K. Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase). Science 273: 245-248, 1996.
30. Kishi T, Hirooka Y, Masumoto A, Ito K, Kimura Y, Inokuchi K, Tagawa T, Shimokawa H, Takeshita A, Sunagawa K. Rho-kinase inhibitor improves increased vascular resistance and impaired vasodilation of the forearm in patients with heart failure. Circulation 11: 2741-2747, 2005.
31. Lai A, Frishman W. Rho-kinase inhibition in the therapy of cardiovascular disease. Cardiol Rev 13: 285-292, 2005.
32. Lee DL, Webb RC, Jin L. Hypertension and RhoA/Rho-kinase signaling in the vasculature: highlights from the recent literature. Hypertension 44: 796-799, 2004.
33. Leung SW, Cheng X, Lim SL, Pang CC. Augmented pulmonary vascular and venous constrictions to N(G)-nitro-L-arginine methyl ester in rats with monocrotaline-induced pulmonary hypertension. Pharmacology 69: 164-170, 2003.
34. Leung T, Manser E, Tan L, Lim L. A novel serine/threonine kinase binding the Ras-related RhoA GTPase which translocates the kinase to peripheral membranes. J Biol Chem 270: 29051-29054, 1995.
35. Li F, Xia W, Li A, Zhao C, Sun R. Long-term inhibition of Rho-kinase with fasudil attenuates high flow induced pulmonary artery remodeling in rats. Pharmacol Res 55: 64-71, 2007.
36. Lohn M, Steioff K, Bleich M, Busch AE, Ivashchenko Y. Inhibition of Rho-kinase stimulates nitric oxide-independent vasorelaxation. Eur J Pharmacol 507: 179-186, 2005.
37. Masumoto A, Hirooka Y, Shimokawa H, Hironaga K, Setoguchi S, Takeshita A. Possible involvement of Rho-kinase in the pathogenesis of hypertension in humans. Hypertension 38: 1307-1310, 2001.
38. Masumoto A, Mohri M, Shimokawa H, Urakami L, Usui M, Takeshita A. Suppression of coronary artery spasm by the Rho-kinase inhibitor fasudil in patients with vasospastic angina. Circulation 105: 1545-1547, 2002.
39. Matsui T, Amano M, Yamamoto T, Chihara K, Nakafuku M, Ito M, Nakano T, Okawa K, Iwamatsu A, Kaibuchi K. Rho-associated kinase, a novel serine/threonine kinase, as a putative target for small GTP binding protein Rho. EMBO J 15: 2208-2216, 1996.
40. Matsui T, Maeda M, Doi Y, Yonemura S, Amano M, Kaibuchi K, Tsukita S, Tsukita S. Rho-kinase phosphorylates COOH-terminal threonines of ezrin/radixin/moesin (ERM) proteins and regulates their head-to-tail association. J Cell Biol 140: 647-657, 1998.
41. Nagaoka T, Fagan K, Gebb S, Morris Suzuki T, Shimokawa H, McMurthy I, Oka M. Inhaled Rho-kinase inhibitors are potent and selective vasodilators in rat pulmonary hypertension. Am J Respir Crit Care Med 171: 494-499, 2005.
42. Nagaoka T, Gebb SA, Karoor V, Homma N, Morris K, McMurtry I, Oka M. Involvement of RhoA/Rho-kinase signaling in pulmonary hypertension of the fawn-hooded rat. J Appl Physiol 100: 996-1002, 2006.
43. Nagaoka T, Morio Y, Casanova N, Bauer N, Gebb S, McMurtry I, Oka M. Rho/Rho-kinase signaling mediates increased basal pulmonary vascular tone in chronically hypoxic rats. Am J Physiol Lung Cell Mol Physiol 287: L665-L672, 2004.
44. Nagumo H, Sasaki Y, Ono Y, Okamoto H, Seto M, Takuwa Y. Rho-kinase inhibitor HA-1077 prevents Rho-mediated myosin phosphatase inhibition in smooth muscle cells. Am J Physiol Cell Physiol 278: C57-C65, 2000.
45. Nohira A, Grunert ME, Rikitake Y, Noma K, Prsic A, Ganz P, Liao JK, Creager MA. Rho-kinase inhibition improves endothelial function in human subjects with coronary artery disease. Circ Res 99: 1426-1432, 2006.
46. Ohtsu H, Suzuki H, Nakashima H, Dhobale S, Frank GD, Motley ED, Eguchi S. Angiotensin II signal transduction through small GTP-binding proteins: mechanism and significance in vascular smooth muscle cells. Hypertension 48: 534-540, 2006.
47. Oka M, Homma N, Taraseviciene-Stewart L, Morris KG, Kraskauskas D, Burns N, Voelkel NF, McMurtry IF. Rho-kinase-mediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats. Circ Res 100: 923-929, 2007.
48. Parker T, Roe G, Grover T, Abman S. Rho-kinase activation maintains high pulmonary vascular resistance in the ovine fetal lung. Am J Physiol Lung Cell Mol Physiol 291: L976-L982, 2006.
49. Peterson DA, Peterson DC, Archer S, Weir EK. The nonspecificity of nitric oxide synthase inhibitors. Biochem Biophys Res Commun 187: 797-801, 1992.
50. Rikitake Y, Liao JK. ROCKs as therapeutic targets in cardiovascular diseases. Expert Rev Cardiovasc Ther 3: 441-451, 2005.
51. Shimokawa H. Rho-kinase as a novel therapeutic target in treatment of cardiovascular diseases. J Cardiovasc Pharmacol 39: 319-327, 2002.
52. 2+ sensitivity of smooth muscle and non-muscle myosin II: modulated by G proteins, kinases, and myosin phosphatase. Physiol Rev 83: 1325-1358, 2003.
53. Uehata M, Ishizaki T, Satoh H, Ono T, Kawahara T, Morishita T, Tamakawa H, Yamagami K, Inui J, Maekawa M, Narumiya S. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 389: 990-994, 1997.
54. 2+ signaling in hypoxic pulmonary vasoconstriction: effects of myosin light chain and Rho kinase antagonists. Am J Physiol Lung Cell Mol Physiol 293: L674-L685, 2007.
55. Wilson PS, Thompson WJ, Moore TM, Khimenko PL, Taylor AE. Perfusate viscosity and hematocrit determine pulmonary nitric oxide synthesis and circulating cyclic GMP. J Surg Res 70: 75-83, 1997.
56. Xing X, Gan Y, Wu S, Chen P, Zhou R, Xiang X. Rho-kinase as a potential therapeutic target for the treatment of pulmonary hypertension. Drug News Perspect 19: 517-522, 2006.